For research use only. Not for therapeutic Use.
AZD1152-HQPA (Cat.No:I004690) is an Aurora kinase B inhibitor that targets cell division and proliferation. It is a prodrug of AZD1152 and is rapidly converted to its active form in vivo. AZD1152-HQPA is being developed as a potential anticancer agent and has shown promising results in preclinical studies. Clinical trials are ongoing to assess its safety and efficacy.
| Catalog Number | I004690 |
| CAS Number | 722544-51-6 |
| Synonyms | 2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide |
| Molecular Formula | C₂₆H₃₀FN₇O₃ |
| Purity | ≥95% |
| Target | Epigenetics |
| Solubility | 10mM in DMSO |
| Storage | 3 years -20℃ powder |
| IC50 | 0.37 nM |
| IUPAC Name | 2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide |
| InChI | InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33) |
| InChIKey | QYZOGCMHVIGURT-UHFFFAOYSA-N |
| SMILES | CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO |
| Reference | </br>1:Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA. Zekri A, Ghaffari SH, Yaghmaie M, Estiar MA, Alimoghaddam K, Modarressi MH, Ghavamzadeh A.Mol Neurobiol. 2016 Apr;53(3):1808-1823. doi: 10.1007/s12035-015-9139-9. Epub 2015 Mar 11. PMID: 25752998 </br>2:AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Zekri A, Ghaffari SH, Ghanizadeh-Vesali S, Yaghmaie M, Salmaninejad A, Alimoghaddam K, Modarressi MH, Ghavamzadeh A.Tumour Biol. 2015 Feb;36(2):623-32. doi: 10.1007/s13277-014-2664-8. Epub 2014 Oct 3. PMID: 25277659 </br>3:The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16. PMID: 20159992 Free Article</br>4:Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Walsby E, Walsh V, Pepper C, Burnett A, Mills K.Haematologica. 2008 May;93(5):662-9. doi: 10.3324/haematol.12148. Epub 2008 Mar 26. PMID: 18367484 Free Article |
